Published in Gene Therapy Weekly, April 20th, 2006
"The NIS gene is currently explored in several trials to eradicate experimental cancer with radiodine (I-131) by its beta-emission. We recently characterized NIS-specific cellular uptake of an alternative halide, radioastatine (At-211), which emits high-energy alpha-particles.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.